報價延遲最少15分鐘:2024/09/28 04:14 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.92 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.35/-1.25
|
|
企業價值
458.45M
|
| 資產負債 |
|
每股賬面淨值
-2.15
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
1.23
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/09/28 04:14 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy. |